Annovis Bio up on full enrollment in Parkinson's disease study

Annovis Bio

08/06/2023 13:21

** Shares of drug developer Annovis Bio Inc  ANVS.N  rise
17.2% at $16.4 before the bell
    ** Co completes enrollment in late-stage trial testing the
use of its lead compound, buntanetap, to treat Parkinson's
disease, a progressive disorder affecting the nervous system
    ** Says it has reached full enrollment in a record nine
months after it began 
    ** Adds, since the first patient was dosed in late August
2022, over 640 patients have been screened and a total of 520
patients enrolled with 67 sites 
    ** As of last close, stock up 4.10% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))